Clinical Trials on Motor Performance in Australia

Total 74 results

PepsiCo Global R&D

Completed

Nutritional Intervention to Enhance Sleep Quality and Quantity in Athletes

Sleep | Cognitive Performance | Balance | Physical Performance

Australia
Johnson & Johnson Vision Care, Inc.

Completed

Evaluating the Impact of JJVC Senofilcon A - Based Contact Lens With New UV-blocker on Day and Night Driving Performance

Visual Performance

Australia
Monash University

Recruiting

Effects of Time of Day and Nut Intake on Cognitive Performance

Cognitive Performance

Australia
Schulthess Klinik

Completed

The i-GelTM. A Randomized, Crossover Study With the Laryngeal Mask Airway ProSealTM in Anesthetized Pediatric Patients

Device Success Rate | Device Performance

Switzerland, Austria
University of Salzburg
Johannes Gutenberg University Mainz; Paracelsus Medical University

Completed

The 10/7 HIIT Shock Cycle Study: Effectiveness of 10 HIIT Sessions in 7 Days (THESIS)

Healthy | Performance | Athlete

Austria
Murdoch Childrens Research Institute
University of Melbourne

Completed

Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age (VIBeS-2)

Neurodevelopmental Disorders | Motor Activity | Developmental Coordination Disorder | Preterm Infant

Australia
FH Campus Wien, University of Applied Sciences

Completed

SensoGrip - a Pressuresensitive Writing System (SensoGrip)

Developmental Delay in Fine Motor Function (Disorder)

Austria
University of Melbourne
Monash University; Western Sydney Local Health District; Royal Prince Alfred... and other collaborators

Recruiting

Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease (3TLA)

Motor Neuron Disease / Amyotrophic Lateral Sclerosis

Australia
argenx

Recruiting

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA+)

Multifocal Motor Neuropathy (MMN)

United Kingdom, Spain, United States, Italy, Netherlands, Germany, France, Belgium, Canada, Poland, Austria
Implicit Bioscience

Withdrawn

IC14 for Treatment of Amyotrophic Lateral Sclerosis

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Implicit Bioscience
Royal Brisbane and Women's Hospital

Completed

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
The Florey Institute of Neuroscience and Mental...
The University of Queensland; Mobius Medical Pty Ltd.

Recruiting

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS (AMBALS)

Amyotrophic Lateral Sclerosis

Australia
Implicit Bioscience

Withdrawn

IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Australia
Brain Sentinel

Unknown

An Exploratory Trial Using sEMG to Differentiate PNES From Epileptic Seizures

Epilepsy | Non-Epileptic Seizure | Motor Seizure

Austria
Spinogenix
Novotech (Australia) Pty Limited

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants

Amyotrophic Lateral Sclerosis

Australia
Gold Coast Hospital and Health Service
Bod Australia

Active, not recruiting

EMERALD TRIAL Open Label Extension Study (EMERALD-OLE)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Cannabis | CBD

Australia
Collaborative Medicinal Development Pty Limited

Unknown

CuATSM Compared With Placebo for Treatment of ALS/MND

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Active, not recruiting

ALS Treatment Extension Study

Amyotrophic Lateral Sclerosis

Australia
PharmAust Ltd
Macquarie University, Australia; Calvary Health Care Bethlehem

Recruiting

An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease

Motor Neuron Disease

Australia
argenx

Active, not recruiting

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA)

Multifocal Motor Neuropathy

United States, France, Germany, Belgium, Italy, Netherlands, Canada, United Kingdom, Austria, Poland, Spain
PharmAust Ltd
Macquarie University, Australia; FightMND; Calvary Health Care Bethlehem

Completed

A Study of Monepantel in Individuals With Motor Neurone Disease

Motor Neuron Disease

Australia
Macquarie University, Australia
King's College London; Stichting TRICALS Foundation

Recruiting

Triumeq in Amyotrophic Lateral Sclerosis (LIGHTHOUSE II)

Amyotrophic Lateral Sclerosis

Australia, New Zealand
Gold Coast Hospital and Health Service
Bod Australia

Active, not recruiting

Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Macquarie University, Australia
ZZ Biotech, LLC

Completed

3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Completed

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Amyotrophic Lateral Sclerosis

Australia
Clene Nanomedicine
Clene Australia Pty Ltd

Completed

Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) (RESCUE-ALS)

Amyotrophic Lateral Sclerosis

Australia
Collaborative Medicinal Development Pty Limited

Completed

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Clene Nanomedicine

Active, not recruiting

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Amyotrophic Lateral Sclerosis

Australia
The University of Queensland
King's College London; UMC Utrecht; Julius Clinical; FightMND

Completed

Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS) (MetFlex)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Netherlands, United Kingdom, Australia
Neuroscience Trials Australia
Macquarie University, Australia; Calvary Health Care Bethlehem; Westmead Hosptial and other collaborators

Completed

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). (Lighthouse)

Amyotrophic Lateral Sclerosis

Australia
Stichting TRICALS Foundation
Research Foundation Flanders; Stichting ALS Nederland; Fight MND; MNDA; Thierry Latran... and other collaborators

Recruiting

Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Belgium, Netherlands, United Kingdom, Sweden, Spain, Australia
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Amyotrophic Lateral Sclerosis

Australia, Sweden, Finland, United States
Orion Corporation, Orion Pharma

Terminated

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension (REFALS-ES)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Germany, Belgium, Finland, Spain, Austria, Italy, France, Ireland, Netherlands, Sweden, United Kingdom
Sydney Children's Hospitals Network
Johns Hopkins University; Children's Hospital of Philadelphia; University of... and other collaborators

Unknown

Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)

Charcot-Marie-Tooth Disease

United States, Australia, Italy
Hoffmann-La Roche

Active, not recruiting

A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (Rainbowfish)

Muscular Atrophy, Spinal

United States, Belgium, Brazil, Russian Federation, Australia, Taiwan, Poland
Orion Corporation, Orion Pharma

Completed

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Austria, United Kingdom, Germany, Finland, Spain, France, Italy, Sweden, Netherlands, Belgium, Ireland
Woolsey Pharmaceuticals

Active, not recruiting

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) (REAL)

Amyotrophic Lateral Sclerosis

United States, Australia
Charite University, Berlin, Germany
Boris Canessa ALS Stiftung

Recruiting

Neurofilament Light Chain in Amyotrophic Lateral Sclerosis (NfL-ALS)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Germany, Austria
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Cytokinetics
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) (FORTITUDE-ALS)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Australia, Canada, Ireland, Spain
Novartis Gene Therapies
PRA Health Sciences

Completed

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 (SPR1NT)

Spinal Muscular Atrophy

United States, United Kingdom, Australia, Belgium, Canada, Japan
Cytokinetics

Terminated

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)

Amyotrophic Lateral Sclerosis

United States, Germany, Spain, Australia, United Kingdom, Canada, France, Belgium, Denmark, Ireland, Italy, Netherlands, Poland, Portugal, Sweden, Switzerland
Synchron Medical, Inc.

Withdrawn

SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Paralysis | Amyotrophic Lateral Sclerosis | Muscular Dystrophies | Neurologic Disorder | Spinal Muscular Atrophy | Spinal Cord Injury | Stroke, Lacunar | Upper Limb Injury | Paralysis; Stroke | Stroke, Brainstem

Australia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (SMART)

Spinal Muscular Atrophy

Taiwan, Belgium, Canada, United States, Australia, France, Italy, Portugal, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam (STRENGTH)

Spinal Muscular Atrophy

Japan, Belgium, Spain, Canada, United States, Australia, Italy, France, Netherlands
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Spain, Italy, Thailand, Turkey, Australia, Taiwan
Sunovion

Completed

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Motor OFF Episodes Associated With Parkinson's Disease

Spain, United Kingdom, Germany, Italy, Austria, France
Novartis Pharmaceuticals

Recruiting

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (SPECTRUM)

Spinal Muscular Atrophy (SMA)

Spain, Canada, Taiwan, Belgium, Japan, Italy, Singapore, United Kingdom, France, Australia, Denmark, United States
Dr. Rebecca Schule
German Federal Ministry of Education and Research; German Center for Neurodegenerative...

Recruiting

Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders (HSP-PBP)

Hereditary Spastic Paraplegia

Austria, Germany, Italy
Biogen

Active, not recruiting

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NURTURE)

Spinal Muscular Atrophy

United States, Taiwan, Israel, Australia, Qatar, United Kingdom, Turkey, Italy, Germany, Argentina, Canada

Clinical Trials on Motor Performance in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations